Matthew Korenberg's most recent trade in Lifecore Biomedical Inc was a trade of 19,506 Common Stock done . Disclosure was reported to the exchange on July 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lifecore Biomedical Inc | Matthew E. Korenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2025 | 19,506 | 44,060 (0%) | 0% | - | Common Stock | |
| Palvella Therapeutics Inc. | Matthew Korenberg E. | CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 123,559 | 123,559 | - | - | Non-Qualified Stock Option (right to buy) | |
| Palvella Therapeutics Inc. | Matthew Korenberg E. | CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 5,373 | 5,373 | - | - | Incentive Stock Option (right to buy) | |
| Palvella Therapeutics Inc. | Matthew Korenberg | CFO, Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2024 | 167,100 | 167,100 | - | - | Stock Option (right to buy) | |
| Lifecore Biomedical Inc | Matthew Korenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Aug 2024 | 24,554 | 24,554 (0%) | 0% | - | Common Stock | |
| Ligand Pharmaceuticals, In... | Korenberg Matthew | PRESIDENT & CHIEF OPERATING | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.61 per share. | 05 Dec 2023 | 1,984 | 97,140 (0%) | 0% | 59.6 | 118,266 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | PRESIDENT & CHIEF OPERATING | Other type of transaction at price $ 56.78 per share. | 30 Jun 2023 | 376 | 99,124 (0%) | 0% | 56.8 | 21,349 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 24,628 | 24,628 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 9,069 | 98,748 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.98 per share. | 15 Feb 2023 | 2,890 | 89,679 (0%) | 0% | 73.0 | 210,912 | Common Stock |
| Qualigen Therapeutics Inc | Matthew Korenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Other type of transaction at price $ 85.91 per share. | 30 Jun 2021 | 247 | 39,690 (0%) | 0% | 85.9 | 21,220 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 172.46 per share. | 15 Feb 2021 | 969 | 39,443 (0%) | 0% | 172.5 | 167,114 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 172.46 per share. | 15 Feb 2021 | 906 | 40,412 (0%) | 0% | 172.5 | 156,249 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 172.46 per share. | 15 Feb 2021 | 434 | 41,318 (0%) | 0% | 172.5 | 74,848 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 11,591 | 11,591 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 10,819 | 41,752 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2021 | 4,803 | 32,373 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2021 | 2,305 | 28,241 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.01 per share. | 25 Jan 2021 | 1,440 | 30,933 (0%) | 0% | 156.0 | 224,654 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.01 per share. | 25 Jan 2021 | 671 | 27,570 (0%) | 0% | 156.0 | 104,683 | Common Stock |